Eisai Raises U.S. Oncology Business Weight With MGI Pharma Acquisition
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai registered swift benefits from its acquisition of MGI Pharma with oncology revenues accounting for 10 percent of its global sales, Eisai CEO Haruo Naito told an Oct. 31 earnings conference
You may also be interested in...
Roche's Chugai Licenses Innovative Antibody Technology To Accelerate Drug Discovery
Roche Japan unit Chugai Pharmaceutical Nov. 30 announced a licensing agreement with Tokyo-based new drug discovery firm Biocomber. Chugai will use Biocomber proprietary cell-free protein synthesis technology Puresystem to speed up global antibody drug development
Roche's Chugai Licenses Innovative Antibody Technology To Accelerate Drug Discovery
Roche Japan unit Chugai Pharmaceutical Nov. 30 announced a licensing agreement with Tokyo-based new drug discovery firm Biocomber. Chugai will use Biocomber proprietary cell-free protein synthesis technology Puresystem to speed up global antibody drug development
Eisai Plans R&D Revamp To Turn The Development Tide
Six autonomous product creation units to focus on neuroscience, oncology, antibodies and immunological anti-inflammatory diseases, with units also focused on late stage drugs and Japanese clinical research.